Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...

Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...

Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease ROCHESTER, N.Y., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VX15 as a potential...

Vaccinex, Inc. Announces the Initiation of a Phase 2 Clinical Trial of Its Investigational VX15/2503 Antibody in Huntington's Disease (the SIGNAL Trial) ROCHESTER, N.Y., June 24, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that it has initiated a Phase 2 clinical trial to assess the safety, tolerability and efficacy of anti-semaphorin 4D...